Enzo Biochem Reports Results of its Annual Meeting of Shareholders
FOR IMMEDIATE RELEASE All Four Proposals Approved NEW YORK, NY, April 12, 2022 (GLOBE NEWSWIRE)…
FOR IMMEDIATE RELEASE All Four Proposals Approved NEW YORK, NY, April 12, 2022 (GLOBE NEWSWIRE)…
NEWTON, Mass. and GENEVA, April 12, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER)…
– Live moderated video webcast fireside chat with Dr. Klaus Paulini, CEO and Giuliano La…
BASKING RIDGE, N.J., April 12, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”…
CC-42344 administered orally as a single 100 mg or 200 mg dose in healthy adults…
SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company…
Two Phase 3 controlled trials with substantially similar design to enroll 1,200 subjects with diabetic…
Mean Baseline Adjusted Epinephrine Concentration over Time by Treatment, 0-2h Mean Baseline Adjusted Epinephrine Concentration…
Former Microsoft and SomaLogic executives join senior leadership team of company developing platform for comprehensively…
Molecular Assemblies has pioneered Fully Enzymatic Synthesis™ (or FES™) technology with an in-process purification step…
The poster, featuring the phase 2 pharmacology study promising results, was selected and featured during…
SYDNEY, Australia, April 12, 2022 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company…
Presentation evaluates the addition of D-PLEX₁₀₀ to the surgical site infection standard of care prophylaxis…
– Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy…
— Canada’s Top Two Cannabis Market Leaders to Join Forces, Strengthening Operations and Unlocking up…
TriTAC-XR demonstrates extended release mechanism that confirms accumulation of active drug which improves therapeutic index…
– Expansion will supply clinical grade cNeT for ongoing Phase I/IIa clinical trials and support…
– First patient dosed in Phase 1/2 clinical trial in ABCC6 Deficiency – – Preliminary…
Presentations from multiple pipeline programs feature clinical and preclinical data demonstrating the unique biology of…
Phase I/II trial initiation expected in 3Q 2022 SUNNYVALE, Calif., April 12, 2022 (GLOBE NEWSWIRE)…